Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | MDM4 | O15151 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.42 |
| ▸ | TNF | P01375 | 3/20 | 0.42 |
| ▸ | TLR2 | O60603 | 2/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30133500 | 0.86 | MDM2 (0.47) | MDM2MDM4TP53SLC17A5TNF | |
| SCHEMBL22552766 | 0.81 | MDM2 (0.48) | MDM2MDM4TP53SLC17A5TNF | |
| SCHEMBL22579992 | 0.81 | MDM2 (0.48) | MDM2MDM4TP53SLC17A5TNF | |
| SCHEMBL22433327 | 0.81 | MDM2 (0.48) | MDM2MDM4TP53SLC17A5TNF | |
| SCHEMBL20825773 | 0.80 | MDM2 (0.48) | MDM2MDM4TP53SLC17A5TNF | |
| SCHEMBL24633712 | 0.78 | MDM4 (0.55) | MDM2MDM4TP53SLC17A5TNF | |
| SCHEMBL25177902 | 0.78 | MDM4 (0.55) | MDM2MDM4TP53SLC17A5TNF | |
| SCHEMBL25216631 | 0.78 | MDM4 (0.55) | MDM2MDM4TP53SLC17A5TNF | |
| SCHEMBL29855105 | 0.78 | MDM4 (0.55) | MDM2MDM4TP53SLC17A5TNF | |
| SCHEMBL22433653 | 0.78 | BACE1 (0.52) | MDM2MDM4TP53TNFTLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358951-B2 | Cyclic peptide antibiotics | GENENTECH, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| US-20230025834-A1 | CYCLIC PEPTIDE ANTIBIOTICS | GENENTECH, INC. (US) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230025834-A1 | CYCLIC PEPTIDE ANTIBIOTICS | NPPA, LNPEP, CLPP | MDM2 2362/4885MDM4 3536/4885TP53 2216/4885 |
| US-12358951-B2 | Cyclic peptide antibiotics | NPPA, LNPEP, CLPP | MDM2 2362/4885MDM4 3536/4885TP53 2216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.